Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
February 28, 2022 4:03 PM ESTNovavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.
GUIDANCE:
Novavax sees FY2022 revenue of $4-5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
... More